Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports

OBJECTIVE: Lung cancer remains the leading cause of malignant tumor-related death globally. There is mounting evidence that a large proportion of patients harboring epidermal growth factor receptor (EGFR) mutation and treated with EGFR TKI experience oligoprogressive disease. The optimal treatment s...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Xuefei, Zhou, Jia, Qian, Caihua, Gao, Liliang, Wang, Bin, Feng, Xueren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369376/
https://www.ncbi.nlm.nih.gov/pubmed/32764966
http://dx.doi.org/10.2147/OTT.S257431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369376/
https://www.ncbi.nlm.nih.gov/pubmed/32764966
http://dx.doi.org/10.2147/OTT.S257431

Ejemplares similares